

**GSK and Birmingham and Solihull CCG. COPD: Risk Stratification and management optimisation for patients in Primary Care, in line with national guidelines and strategy**

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Birmingham and Solihull CCG and GSK are undertaking a Joint Working project. The aims are to:

1. Prioritise patients with risk factors for review
2. Ensure alignment to national NICE COPD management and prescribing guidelines and support CCG Universal Offer through providing review support to practices
  - a. Emphasising the importance of high-impact low-cost interventions for all (‘flu vaccination, smoking cessation support, pulmonary rehabilitation referral) and of inhaler technique check and self-management plans
  - b. Reinforcing the appropriate use of triple therapy as guided by the NICE guideline
  - c. Ensure patients receive appropriate therapy in line with national guidelines
  - d. Minimise the number of inhalers and the number of different types of inhaler used by each person as far as possible
  - e. Prescribing in line with local formulary
3. Align to national prescribing strategies such as Investment and Impact Fund ‘Help create a more sustainable NHS’ enhanced service where clinically appropriate for patients

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from July 2022 to August 2023.

**Intended Benefits:**

Patients	<ul style="list-style-type: none"> <li>• Full review in line with national guidelines based on current therapy and risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle e.g. addressing the backlog) potentially increasing volume of those receiving a review, potentially leading to better outcomes</li> <li>• Optimisation of both non-pharmacological &amp; pharmacological management</li> <li>• Potentially fewer COPD- related interventions, including hospital admissions</li> <li>• Better informed about COPD management and treatment options</li> <li>• COPD managed in accordance with current best practice clinical guidance</li> <li>• Better experience of the healthcare system – access to an Interface Clinical Service Clinical pharmacist and/or upskilled primary care clinician at their own GP practice</li> </ul>
NHS	<ul style="list-style-type: none"> <li>• Realisation of value-based healthcare objectives of improved patient outcomes with reduced costs</li> <li>• Support with risk stratification</li> <li>• Additional resource support to address the backlog a COPD patients not having a review during the COVID pandemic. This additional resource will also support practices in achieving the Universal Offer criteria</li> <li>• Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting for sustainability</li> <li>• Insight into COPD population at practice and federation to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care</li> <li>• Opportunity to upskill primary care doctors and nurses</li> <li>• Prescribing inline with national sustainability aspirations where clinically appropriate for patients</li> <li>• An environment to support the delivery of improved health outcomes for the COPD patient population</li> <li>• Potential reduction in COPD- related interventions, including hospital admissions</li> </ul>
GSK	<ul style="list-style-type: none"> <li>• Helps GSK to live its value of being a patient focussed company.</li> </ul>

## GlaxoSmithKline (UK Ltd) and NHS Birmingham and Solihull CCG Executive Summary

	<ul style="list-style-type: none"><li>• Demonstrate partnership working</li><li>• Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme</li><li>• Potential increase in prescribing of on-formulary dry powder inhaler products within class if clinically appropriate for patients, aligned to the sustainability agenda – which may include GSK products</li><li>• Increase in the appropriate use of medicines licensed for COPD aligned to local/national guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.</li><li>• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care</li><li>• Broadening of professional network</li></ul>
--	---